Suppressing the expression of the high mobility group box 1 (HMGB1) gene could reduce glutamine metabolic activity in hepatocellular carcinoma cells and significantly enhance the response of HCC cells to PD-L1 antagonists [8]. This evidence concerns the gene HMGB1 and hepatocellular carcinoma.